Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 8/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 5/20 | 1.00 |
| ▸ | PRKCA | P17252 | 5/20 | 1.00 |
| ▸ | PRKCH | P24723 | 5/20 | 1.00 |
| ▸ | PRKCI | P41743 | 5/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 5/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 5/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 5/20 | 1.00 |
| ▸ | PRKCG | P05129 | 4/20 | 1.00 |
| ▸ | PRKCB | P05771 | 4/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 4/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 7/20 | 0.90 |
| ▸ | KDR | P35968 | 7/20 | 0.90 |
| ▸ | FLT3 | P36888 | 5/20 | 0.84 |
| ▸ | MYLK | Q15746 | 4/20 | 0.84 |
| ▸ | CDK4 | P11802 | 3/20 | 0.84 |
| ▸ | CDK2 | P24941 | 3/20 | 0.84 |
| ▸ | MAP3K11 | Q16584 | 3/20 | 0.84 |
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.84 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14825402 | 1.00 | PRKCQ (1.00) | PRKCQPRKD3PRKCAPRKCHPRKCI | |
| SCHEMBL13168059 | 1.00 | PRKCQ (1.00) | PRKCQPRKD3PRKCAPRKCHPRKCI | |
| SCHEMBL29451226 | 1.00 | PRKCQ (1.00) | PRKCQPRKD3PRKCAPRKCHPRKCI | |
| SCHEMBL16931994 | 1.00 | PRKCQ (1.00) | PRKCQPRKD3PRKCAPRKCHPRKCI | |
| SCHEMBL3747539 | 1.00 | PRKCQ (1.00) | PRKCQPRKD3PRKCAPRKCHPRKCI | |
| SCHEMBL14207925 | 1.00 | PRKCQ (1.00) | PRKCQPRKD3PRKCAPRKCHPRKCI | |
| SCHEMBL13246716 | 0.94 | PRKCQ (0.89) | PRKCQPRKD3PRKCAPRKCHPRKCI | |
| K-252A SCHEMBL24112155 | 0.92 | NTRK1 (1.00) | PRKCQPRKD3PRKCAPRKCHPRKCI | |
| K-252A SCHEMBL968886 | 0.92 | NTRK1 (1.00) | PRKCQPRKD3PRKCAPRKCHPRKCI | |
| SCHEMBL21132411 | 0.92 | NTRK1 (0.85) | PRKCQPRKD3PRKCAPRKCHPRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112689758-B | Device and method for checking the effect of a drug on microorganisms | 上海宜晟生物科技有限公司 | 2025-03-28 | — | — | CN | claimed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | claimed |
| US-11725227-B2 | Devices and methods for examining drug effects on microorganisms | ESSENLIX CORPORATION (US) | 2023-08-15 | — | — | US | claimed |
| WO-2023039578-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2023-03-16 | — | — | WO | claimed |
| US-12594275-B2 | Immunophilin binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-04-07 | — | — | US | disclosed |
| US-12558356-B2 | Immunophilin binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-24 | — | — | US | disclosed |
| US-12533359-B2 | Method for preventing hair loss | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-01-27 | — | — | US | disclosed |
| US-20250304916-A1 | METHODS AND COMPOSITIONS FOR GENERATING VASCULAR LEPTOMENINGEAL CELLS | TRAILHEAD BIOSYSTEMS INC (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250129075-A1 | PRODUCTION METHOD FOR T CELLS OR NK CELLS, MEDIUM FOR CULTURING T CELLS OR NK CELLS, METHOD FOR CULTURING T CELLS OR NK CELLS, METHOD FOR MAINTAINING UNDIFFERENTIATED STATE OF UNDIFFERENTIATED T CELLS, AND GROWTH-ACCELERATING AGENT FOR T CELLS OR NK CELLS | KIRIN HOLDINGS KABUSHIKI KAISHA, (JP) | 2025-04-24 | — | — | US | disclosed |
| US-20250108052-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-04-03 | — | — | US | disclosed |
| CN-112689758-B | Device and method for checking the effect of a drug on microorganisms | 上海宜晟生物科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-12168781-B2 | Production method for T cells or NK cells, medium for culturing T cells or NK cells, method for culturing T cells or NK cells, method for maintaining undifferentiated state of undifferentiated T cells, and growth-accelerating agent for T cells or NK cells | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2024-12-17 | — | — | US | disclosed |
| US-20230149404-A1 | Treatment Of Adipocytes | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2023-05-18 | — | — | US | disclosed |
| CN-110785170-B | Treatment of adipocytes | 梅里奥尔医药I公司 | 2023-03-28 | — | — | CN | disclosed |
| WO-2023039578-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2023-03-16 | — | — | WO | disclosed |
| US-20230063768-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-03-02 | — | — | US | disclosed |
| US-11534442-B2 | Treatment of adipocytes | MELIOR PHARMACEUTICALS I, INC. (US) | 2022-12-27 | — | — | US | disclosed |
| US-20220249509-A1 | METHOD FOR PREVENTING HAIR LOSS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-08-11 | — | — | US | disclosed |
| US-20220193242-A1 | IMMUNOPHILIN-DEPENDENT INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-23 | — | — | US | disclosed |
| EP-3993764-A1 | METHOD FOR PREVENTING HAIR LOSS | Icahn School of Medicine at Mount Sinai (US) | 2022-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193242-A1 | IMMUNOPHILIN-DEPENDENT INHIBITORS AND USES THEREOF | CD74, CD2BP2, SERPINB1 | PRKCQ 3122/4885PRKD3 3030/4885PRKCA 3488/4885 |
| US-20230149404-A1 | Treatment Of Adipocytes | LIPG, LPL, PNLIP | PRKCQ 167/4885PRKD3 146/4885PRKCA 93/4885 |
| US-20250129075-A1 | PRODUCTION METHOD FOR T CELLS OR NK CELLS, MEDIUM FOR CULTURING T CELLS OR NK CELLS, METHOD FOR CULTURING T CELLS OR NK CELLS, METHOD FOR MAINTAINING UNDIFFERENTIATED STATE OF UNDIFFERENTIATED T CELLS, AND GROWTH-ACCELERATING AGENT FOR T CELLS OR NK CELLS | NFATC1, PBK, CD4 | PRKCQ 1413/4885PRKD3 1097/4885PRKCA 1690/4885 |
| US-20230063768-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | PMP22, MAG, FABP7 | PRKCQ 4127/4885PRKD3 4431/4885PRKCA 4555/4885 |
| US-12594275-B2 | Immunophilin binding agents and uses thereof | CCR1, CCRL2, CCR3 | PRKCQ 4500/4885PRKD3 4067/4885PRKCA 4783/4885 |
| US-20250108052-A1 | IMMUNOPHILIN BINDING AGENTS AND USES THEREOF | SERPINA6, SELPLG, FABP7 | PRKCQ 4275/4885PRKD3 4464/4885PRKCA 4725/4885 |
| US-12168781-B2 | Production method for T cells or NK cells, medium for culturing T cells or NK cells, method for culturing T cells or NK cells, method for maintaining undifferentiated state of undifferentiated T cells, and growth-accelerating agent for T cells or NK cells | CAMK1, CAMK4, NFATC1 | PRKCQ 64/4885PRKD3 126/4885PRKCA 35/4885 |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, CD4, MCL1 | PRKCQ 1247/4885PRKD3 2542/4885PRKCA 1356/4885 |
| US-12533359-B2 | Method for preventing hair loss | MYLK, MYLK3, MYLK2 | PRKCQ 133/4885PRKD3 202/4885PRKCA 76/4885 |
| US-11534442-B2 | Treatment of adipocytes | LIPG, LPL, PNLIP | PRKCQ 167/4885PRKD3 146/4885PRKCA 93/4885 |
| US-12558356-B2 | Immunophilin binding agents and uses thereof | CCRL2, CFB, CCR3 | PRKCQ 4582/4885PRKD3 4342/4885PRKCA 4733/4885 |
| US-20220249509-A1 | METHOD FOR PREVENTING HAIR LOSS | MYLK3, MYLK4, MYLK | PRKCQ 716/4885PRKD3 1222/4885PRKCA 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.